432 related articles for article (PubMed ID: 8689013)
1. [Lung diseases due to opportunistic environmental Mycobacteria in patients uninfected with human immunodeficiency virus. Risk factors, clinical and diagnostic aspects and course].
Martínez Moragón E; Menéndez R; Santos M; Lorente R; Marco V
Arch Bronconeumol; 1996 Apr; 32(4):170-5. PubMed ID: 8689013
[TBL] [Abstract][Full Text] [Related]
2. [Nontuberculous mycobacterial infections of the lung].
Latshang TD; Lo Cascio CM; Russi EW
Ther Umsch; 2011 Jul; 68(7):402-6. PubMed ID: 21728159
[TBL] [Abstract][Full Text] [Related]
3. [Distribution and drug resistance of nontuberculous
Zhang J; Su JR; Ding BC; Liu JW; Yi JL; Yang XY; Wang NH; Wang SM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Mar; 40(3):210-214. PubMed ID: 28297817
[No Abstract] [Full Text] [Related]
4. [Ofloxacin in the treatment of pulmonary changes caused by Mycobacterium avium and Mycobacterium xenopii].
Zwoliński J; Gałazka J
Pneumonol Alergol Pol; 1992; 60(5-6):70-3. PubMed ID: 1290992
[TBL] [Abstract][Full Text] [Related]
5. [Clinical analysis of 96 cases with pulmonary disease caused by nontuberculous mycobacteria].
Xia X; Gui X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Apr; 22(4):239-41. PubMed ID: 11775923
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
7. Distribution of nontuberculous mycobacteria in treated patients with pulmonary disease in Greece - relation to microbiological data.
Manika K; Tsikrika S; Tsaroucha E; Karabela S; Karachaliou I; Bosmi I; Kioumis I; Papavasileiou A
Future Microbiol; 2015; 10(8):1301-6. PubMed ID: 26226382
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of nontuberculous mycobacterial pulmonary diseases: a Korean perspective.
Koh WJ; Kwon OJ; Lee KS
J Korean Med Sci; 2005 Dec; 20(6):913-25. PubMed ID: 16361797
[TBL] [Abstract][Full Text] [Related]
9. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
10. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Research Committee of the British Thoracic Society
Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
[TBL] [Abstract][Full Text] [Related]
11. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China.
Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C
Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316
[TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of atypical mycobacterial infections of the respiratory tract].
Andréjak C; Lescure FX; Schmit JL; Jounieaux V
Rev Mal Respir; 2011 Dec; 28(10):1293-309. PubMed ID: 22152937
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment.
Eur Respir J; 2003 Mar; 21(3):478-82. PubMed ID: 12662005
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.
Int J Tuberc Lung Dis; 2002 Jul; 6(7):628-34. PubMed ID: 12102303
[TBL] [Abstract][Full Text] [Related]
15. Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis.
Al Jarad N; Demertzis P; Jones DJ; Barnes NC; Rudd RM; Gaya H; Wedzicha JA; Hughes DT; Empey DW
Thorax; 1996 Feb; 51(2):137-9. PubMed ID: 8711643
[TBL] [Abstract][Full Text] [Related]
16. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection.
Murray MP; Laurenson IF; Hill AT
Clin Infect Dis; 2008 Jul; 47(2):222-4. PubMed ID: 18532890
[TBL] [Abstract][Full Text] [Related]
18. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
Ye JJ; Wu TS; Chiang PC; Lee MH
J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469
[TBL] [Abstract][Full Text] [Related]
19. Mycobacteria as pathogens of respiratory infection.
Griffith DE
Infect Dis Clin North Am; 1998 Sep; 12(3):593-611. PubMed ID: 9779380
[TBL] [Abstract][Full Text] [Related]
20. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
